Skip to content

Find our latest news, stories and press releases

Delivering long-term value for our stakeholders

Explore career opportunities and more

Impacting health for humanity

  1. Home/
  2. News/
  3. Innovation/
  4. 3 ways Johnson & Johnson is innovating to help fight tuberculosis
lede-3 Ways Johnson & Johnson Is Innovating to Help Fight Tuberculosis.jpg

3 ways Johnson & Johnson is innovating to help fight tuberculosis

It’s one of the world’s deadliest infectious diseases, killing more people each year than HIV/AIDS and malaria combined. We’re taking a look back at the strides the company has made in fighting this preventable illness to help bring us closer to a tuberculosis-free world.

1.4 million. That’s how many people tuberculosis (TB) killed in 2019, despite it being a preventable and treatable disease.

For years, one of the biggest impediments to global efforts to tackle TB has been growing resistance to the most commonly used medicines to treat the disease—in 2019 alone, there were nearly 400,000 new cases of multidrug-resistant TB (MDR-TB), which does not respond to the two most commonly-used TB medications currently available.

There’s also the hurdle of diagnosis: While detection numbers had been on the rise prior to the COVID-19 pandemic, there are still approximately 3 million people living with TB who don’t know they have the disease. And every individual who remains untreated can infect up to 15 additional people over the course of a year, further fueling the TB pandemic.

COVID-19 is also posing new challenges. Not only do people with TB fear that they may be uniquely vulnerable to severe complications from COVID-19 if infected, but the pandemic has also disrupted already stretched systems of delivering TB care.

“COVID-19 is threatening hard-won gains in the fight against TB,” says Ana-Maria Ionescu, TB Access Strategy & Impact Leader, Global Public Health, Johnson & Johnson. “At Johnson & Johnson, we are committed to doing our part, in collaboration with governments and partners, to ensure that patients continue to receive the care they need during these unprecedented times.”

For example, in response to COVID-19 , Johnson & Johnson launched the DR-TB Lifeline QuickFire Challenge , which is providing support to five organizations working to ensure continuity of care for drug-resistant TB (DR-TB) patients in India, the Philippines, South Africa and Ukraine.

Before the pandemic, Johnson & Johnson also launched a historic 10-year initiative in 2018 aimed at helping improve disease detection; broaden access to its novel medicine for MDR-TB; and accelerate research to develop more next-generation medicines.

It’s a critical project—and the company is well on its way to delivering on some of the key commitments.

We’re highlighting some of the strides Johnson & Johnson made through the initiative to help bring us closer to a TB-free world.


3-ways-tuberculosis-infographic-dec-9-02.jpg

Johnson & Johnson’s Quest to End TB

Read about how the company is working to improve detection, broaden access to treatment, and accelerate research and development for the disease over the next decade.

More from Johnson & Johnson

How Johnson & Johnson is advancing the fight against Alzheimer’s disease

After decades of commitment to understanding this neurodegenerative disease, company scientists have developed innovative therapies and tools that can potentially slow its progression and ease the psychological toll on patients and caretakers. A cure is still elusive—but preventing the disease may be within reach.

Is this the end of one-size-fits-all treatments for depression?

Learn how Johnson & Johnson is working to better address the needs of the 7 in 10 people with depression whose treatments aren’t providing enough relief.

What is inflammation?

Inflammation is the body’s natural response to injury or infection. But when it lingers, inflammation can lead to inflammatory bowel disease, psoriasis and rheumatoid arthritis, among other immune-mediated inflammatory diseases. Learn how Johnson & Johnson is innovating to help bring relief to those living with chronic inflammatory conditions.